Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework-Reference-Cited by-同舟云学术

Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework

Published:2017-12-01 Issue:4 Volume:28 Page:589-611
ISSN:1054-3406
Container-title:Journal of Biopharmaceutical Statistics
language:en
Short-container-title:Journal of Biopharmaceutical Statistics

Author:

Nomura Shogo¹²,Hirakawa Akihiro³,Hamada Chikuma¹

Affiliation:

1. Center for Research and Administration and Support, National Cancer Center, Chiba, Japan

2. Department of Information and Computer Technology, Graduate School of Engineering, Tokyo University of Science, Tokyo, Japan

3. Department of Biostatistics and Bioinformatics, The University of Tokyo, Tokyo, Japan

Funder

National Cancer Center Research and Development Fund

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://www.tandfonline.com/doi/pdf/10.1080/10543406.2017.1372775

Reference43 articles.

1. Sample size determination in group-sequential clinical trials with two co-primary endpoints

2. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

3. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

4. Progression-Free Survival: Meaningful or Simply Measurable?

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How is overall survival assessed in randomised clinical trials in cancer and are subsequent treatment lines considered? A systematic review;Trials;2023-11-06

2. Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review;European Journal of Cancer;2021-05

3. Sample Size Determination in Group-Sequential Trials Assessing Interim Futility by Intermediate Composite Endpoints;Statistics in Biopharmaceutical Research;2020-08-24

4. Joint modeling of progression‐free and overall survival and computation of correlation measures;Statistics in Medicine;2019-07-04